Volume | 579,270 |
|
|||||
News | - | ||||||
Day High | 42.30 | Low High |
|||||
Day Low | 41.21 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Celldex Therapeutics Inc | CLDX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
41.68 | 41.21 | 42.30 | 41.97 | 41.79 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
6,141 | 579,270 | $ 41.72 | $ 24,166,967 | - | 22.11 - 53.18 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:02:38 | priorref | 122 | $ 41.97 | USD |
Celldex Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.34B | 55.90M | - | 6.88M | -141.43M | -2.53 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Celldex Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CLDX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 42.71 | 43.42 | 40.415 | 41.43 | 687,790 | -0.74 | -1.73% |
1 Month | 51.50 | 53.18 | 39.50 | 46.12 | 1,234,099 | -9.53 | -18.50% |
3 Months | 39.52 | 53.18 | 34.65 | 43.19 | 982,739 | 2.45 | 6.20% |
6 Months | 27.26 | 53.18 | 22.11 | 36.69 | 861,878 | 14.71 | 53.96% |
1 Year | 35.03 | 53.18 | 22.11 | 35.16 | 688,145 | 6.94 | 19.81% |
3 Years | 20.01 | 57.20 | 15.37 | 35.11 | 633,976 | 21.96 | 109.75% |
5 Years | 5.15 | 57.20 | 1.50 | 24.01 | 681,906 | 36.82 | 714.95% |
Celldex Therapeutics Description
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527. |